The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...

The phase 3 SUCCESSOR-2 trial shows mezigdomide-based therapy improves PFS in R/R multiple myeloma patients previously exposed to lenalidomide.

In this interview, Sagar Lonial, MD, discussed the EXCALIBER-RRMM trial design and the potential role of iberdomide in the ...

First in India successful births using umbilical cord stem cell therapy for severe Asherman's syndrome ...

PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumorsPLN-101095 accelerated ...

Phase 3 MajesTEC-3 trial data demonstrate significant improvements in both progression free survival and overall survival with teclistamab plus daratumumab hyaluronidase-fihj. The approval was ...

Two women suffering from severe Asherman's syndrome have delivered babies after undergoing treatment using umbilical cord-derived mesenchymal stem cells at a private hospital.

PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indicatio ...

In the completed Phase 2 trial in r/r AML, SLS009 in combination with aza/ven met all endpoints, exceeding the pre-specified ORR threshold of 20%, demonstrating strong efficacy and favorable safety ...

The fair value estimate for Johnson & Johnson has been adjusted from US$232.50 to US$237.29 per share, a small move that ...

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

A 39-year-old woman with severe uterine adhesions, which developed after miscarriage treatment, underwent stem cell therapy. Following improvement in menstrual flow and endometrial thickness, embryo ...